Want to see PRCT full AI Analyst Report?

PROCEPT BioRobotics (PRCT) Price & Analysis

659 Followers

PRCT Stock Chart & Stats

$25.14

-$0.85(-0.97%)

At close: Jan 08 4:00 PM EST

$25.14

-$0.85(-0.97%)

Day’s Range― - ―

52-Week Range$17.96 - $60.57

Previous CloseN/A

Volume113.34K

Average Volume (3M)1.72M

Market Cap

$1.09B

Enterprise Value$1.25K

Total Cash (Recent Filing)$245.64M

Total Debt (Recent Filing)$51.66M

Price to Earnings (P/E)―

Beta0.74

Next Earnings

Aug 04, 2026

EPS Estimate

-0.46

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.82

Shares Outstanding56,918,842

10 Day Avg. Volume1,672,506

30 Day Avg. Volume1,715,311

Financial Highlights & Ratios

PEG Ratio10.67

Price to Book (P/B)4.78

Price to Sales (P/S)5.67

P/FCF Ratio-29.95

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$30.00

Price Target Upside19.33% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

EPS Forecast (FY)-1.54

Revenue Forecast (FY)$397.46M

Bulls Say, Bears Say

Bulls Say

Revenue & Procedure GrowthSustained top-line and procedure volume growth indicate durable market adoption of Aquablation. Higher procedure throughput supports recurring consumable demand and expands the installed base, improving long-term revenue visibility as clinical adoption and guideline support continue to drive utilization.

Improving Unit Economics (Gross Margin)Material gross margin expansion to ~64–65% reflects better product mix, pricing power and manufacturing leverage. Higher gross margins increase the amount of revenue available to cover fixed commercial and R&D spend, materially improving the path to sustainable profitability as revenue scales.

Recurring Consumables & ASP StrengthA high-ratio consumable model with handpiece ASP strength creates predictable, repeatable per-procedure revenue tied to usage. Combined with rising system ASPs, this mix supports durable margin per case and recurring revenue that compounds as the installed base and procedure count grow.

Bears Say

Persistent Negative Cash FlowOngoing negative operating and free cash flow means the business consumes material cash to fund growth and clinical programs. Even with improvement versus prior periods, sustained cash burn increases reliance on financing or drawdown of reserves and constrains optionality for investments or returns.

Large Operating Losses & Rising OpExRapidly higher operating expenses to support commercial expansion and trials are widening GAAP and adjusted EBITDA losses. If revenue growth slips or operating leverage lags, elevated fixed costs could delay the transition to consistent profitability and prolong reliance on external funding.

Tariff Headwinds & Execution RiskRising tariff expense is a structural gross-margin headwind unless offset by pricing or refunds. Coupled with back-loaded commercial initiatives and realignment disruption, this raises execution risk that could impair margin progression and delay targeted EBITDA inflection if ramp timing falters.

PROCEPT BioRobotics News

Procept BioRobotics downgraded to Hold from Buy at Truist

Truist downgraded Procept BioRobotics (PRCT) to Hold from Buy with a price target of $25, down from $30,...

19d ago

PRCT

BlackBerry, Take-Two initiations among today’s top calls on Wall Street

The most talked about and market moving research calls around Wall Street are now in one place. Here...

27d ago

Procept BioRobotics initiated with an Outperform at Evercore ISI

Evercore ISI analyst Vijay Kumar initiated coverage of Procept BioRobotics (PRCT) with an Outperform rating and $30 price...

27d ago

PRCT

PROCEPT, Fortescue Trending as Analysts Turn Cautious

Analysts are intrested in these 5 stocks: ( ($PRCT) ) and ( ($FSUMF) ). Here is a breakdown...

17d ago

PRCT

SpaceX initiated, Intel upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

Leerink downgrades Procept BioRobotics to Market Perform, lowers target to $29

As previously reported, Leerink analyst Mike Kratky downgraded Procept BioRobotics (PRCT) to Market Perform from Outperform with a...

1M ago

PRCT

Procept BioRobotics downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Procept BioRobotics (PRCT) to Market Perform from Outperform with a $29 price target Published first on...

1M ago

PRCT

PROCEPT BioRobotics Shareholders Back Board, Pay and Auditor

An announcement from PROCEPT BioRobotics ( ($PRCT) ) is now available. At PROCEPT BioRobotics Corporation’s annual meeting of...

1M ago

PRCT

Analyst Reiterates Buy as Management Reaffirms 2026 Targets and Commercial Restructuring Begins to Deliver Benefits

William Blair analyst Brandon Vazquez has maintained their bullish stance on PRCT stock, giving a Buy rating on...

2M ago

PRCT

Aquablation Gains Stronger Guideline Backing, Supporting Procept’s Long-Term Growth and Buy Rating

William Blair analyst Brandon Vazquez has maintained their bullish stance on PRCT stock, giving a Buy rating today....

2M ago

PRCT

Procept Biorobotics Charts Growth Amid Profit Pressures

Procept Biorobotics Corp. (($PRCT)) has held its Q1 earnings call. Read on for the main highlights of the...

3M ago

PRCT

Procept BioRobotics price target raised to $35 from $28 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Procept BioRobotics (PRCT) to $35 from $28...

3M ago

PRCT

Procept BioRobotics price target raised to $28 from $27 at Baird

Baird raised the firm’s price target on Procept BioRobotics (PRCT) to $28 from $27 and keeps a Neutral...

3M ago

PRCT

PROCEPT BioRobotics: Buy Rating Reaffirmed on Strong Q1 Performance and Multi‑Year Outlook, Price Target Unchanged at $34

In a report released yesterday, Josh Jennings from TD Cowen maintained a Buy rating on PROCEPT BioRobotics, with...

3M ago

PRCT

PRCT FAQ

What was Procept Biorobotics Corp.’s price range in the past 12 months?

Procept Biorobotics Corp. lowest stock price was $17.96 and its highest was $60.57 in the past 12 months.

What is Procept Biorobotics Corp.’s market cap?

Procept Biorobotics Corp.’s market cap is $1.09B.

When is Procept Biorobotics Corp.’s upcoming earnings report date?

Procept Biorobotics Corp.’s upcoming earnings report date is Aug 04, 2026 which is in 14 days.

How were Procept Biorobotics Corp.’s earnings last quarter?

Procept Biorobotics Corp. released its earnings results on Apr 29, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.563 by $0.003.

Is Procept Biorobotics Corp. overvalued?

According to Wall Street analysts Procept Biorobotics Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Procept Biorobotics Corp. pay dividends?

Procept Biorobotics Corp. does not currently pay dividends.

What is Procept Biorobotics Corp.’s EPS estimate?

Procept Biorobotics Corp.’s EPS estimate is -0.46.

How many shares outstanding does Procept Biorobotics Corp. have?

Procept Biorobotics Corp. has 56,918,842 shares outstanding.

What happened to Procept Biorobotics Corp.’s price movement after its last earnings report?

Procept Biorobotics Corp. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.563. Following the earnings report the stock price went up 10.732%.

Which hedge fund is a major shareholder of Procept Biorobotics Corp.?

Currently, no hedge funds are holding shares in PRCT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

PROCEPT BioRobotics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-6.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Procept Biorobotics Corp.

PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.

PROCEPT BioRobotics (PRCT) Earnings & Revenues

Historic Earnings Reports

PRCT Stock 12 Month Forecast

Average Price Target

$30.00

▲(19.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","38":"$38","57":"$57","28.5":"$28.5","47.5":"$47.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,28.5,38,47.5,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.47,24.356923076923074,25.243846153846153,26.13076923076923,27.017692307692307,27.904615384615383,28.79153846153846,29.678461538461537,30.565384615384616,31.45230769230769,32.33923076923077,33.22615384615385,34.113076923076925,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.47,23.97230769230769,24.474615384615383,24.976923076923075,25.479230769230767,25.98153846153846,26.48384615384615,26.986153846153847,27.488461538461536,27.99076923076923,28.49307692307692,28.995384615384616,29.497692307692308,{"y":30,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.47,23.20307692307692,22.936153846153847,22.66923076923077,22.40230769230769,22.135384615384616,21.86846153846154,21.60153846153846,21.334615384615383,21.067692307692308,20.80076923076923,20.533846153846156,20.266923076923078,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.46,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.14,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.36,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.86,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.47,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >